Table 3.
Effect of treatment with COX inhibitors on relative number of cortical macrophages (F4/80-positive), proliferating cells (PCNA-positive), fibrosis (area of basement membrane of Bowman's capsule) and diameter of cortical tubules in mouse kidney sections
| Substance | Number of cortical F4/80-positive cells per index field | Number of PCNA-positive cells per index field | Area of basement membrane (arbitrary units) | Diameter of cortical tubules (µm) |
|---|---|---|---|---|
| Control | 11.2 ± 0.8 | 1.5 ± 0.3 | 0.25 ± 0.03 | 20.67 ± 1.08 |
| SC-236 | 14.5 ± 1.9 | 2.8 ± 0.3 | 0.76 ± 0.11* | 19.15 ± 0.78 |
| DMC | 11.0 ± 1.4 | 0.9 ± 0.2 | 0.23 ± 0.04 | 20.68 ± 1.10 |
| Celecoxib | 12.1 ± 1.1 | 1.4 ± 0.4 | 0.32 ± 0.09 | 20.49 ± 1.33 |
| Rofecoxib | 13.0 ± 1.2 | 2.9 ± 0.5 | 0.85 ± 0.13* | 20.37 ± 1.19 |
| Valdecoxib | 13.5 ± 1.3 | 3.8 ± 0.4 | 0.47 ± 0.11 | 20.28 ± 0.24 |
| Etoricoxib | 13.1 ± 1.2 | 2.0 ± 0.3 | 0.71 ± 0.12 | 19.40 ± 0.70 |
| Lumiracoxib | 12.4 ± 0.9 | 0.9 ± 0.2 | 0.65 ± 0.09 | 19.27 ± 0.23 |
| Naproxen | 9.2 ± 0.9 | 6.7 ± 0.7* | 0.66 ± 0.14 | 19.20 ± 0.86 |
| Diclofenac | 10.2 ± 0.8 | 5.9 ± 0.6* | 0.70 ± 0.13 | 19.14 ± 0.41 |
*
P < 0.05 versus control.
DMC, methyl-celecoxib; PCNA, proliferating cell nuclear antigen.